Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. Some clinicians suggest that adults with ADHD may abuse cocaine in order to self-medicate their ADHD symptoms. Atomoxetine is a drug that has been effective in treating ADHD. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Atomoxetine Hydrochloride; Cocaine

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria for cocaine dependence and adult ADHD

• Describes cocaine as the primary drug of abuse

• Meets DSM-IV criteria for cocaine dependence

Exclusion Criteria:

• Meets DSM-IV criteria for current Axis I psychiatric disorders that require a psychiatric intervention (except ADHD or substance abuse)

• Current major depression

• Unstable physical disorders that might make participation unsafe (e.g., uncontrolled high blood pressure and tachycardia [systolic blood pressure greater than 150 mm Hg, diastolic blood pressure greater than 90 mm Hg, or a sitting heart rate greater than 100])

• Acute hepatitis (individuals with chronic mildly elevated transaminase levels of less than 2 or 3 times the normal limit are not excluded)

• Diabetes

• Coronary vascular disease, as indicated by a history or suspected by an abnormal electrocardiogram

• History of cardiac symptoms

• History of seizures

• Narrow angle glaucoma

• Use of monoamine oxidase inhibitors (MAOIs) within 2 weeks of starting treatment with atomoxetine

• Currently taking prescribed psychotropic medications

• Currently taking medications for the treatment of ADHD

• Known sensitivity to atomoxetine

• Current suicidal ideation or history of suicidal or homicidal behavior within 2 years prior to study entry

• Pregnant or breastfeeding

• Physiologically dependent on any drugs other than nicotine or marijuana

• History of schizophrenia, bipolar disorder, or other psychotic disorders

• Currently taking cough medicine (e.g., dextromethorphan) and/or albuterol